Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation Impact Factor & Information

Publisher: Middle East Society for Organ Transplantation

Journal description

Current impact factor: 0.80

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 0.798
2012 Impact Factor 0.588
2011 Impact Factor 0.813
2010 Impact Factor 0.832
2009 Impact Factor 0.595

Impact factor over time

Impact factor
Year

Additional details

5-year impact 0.73
Cited half-life 3.90
Immediacy index 0.11
Eigenfactor 0.00
Article influence 0.19
Other titles Journal of experimental and clinical transplantation, JECT
ISSN 1304-0855
OCLC 54768546
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Nonmelanoma skin cancers are the most common malignancies in transplant recipients under immunosuppression; nevertheless, appendage tumors also may appear. The onset of several cutaneous neoplasms in transplant patients can cause deterioration in quality of life of these patients. A 62-year-old white woman patient developed several malignant and benign sebaceous neoplasms during an immunosuppressive treatment for a renal transplant. The genetic study showed a mutation in MSH6-eson 1 (c116G>A), without mutations in MLH1 gene and MSH2. A final diagnosis of multiple sebaceous tumors in an immunosuppressed patient without Muir -Torre syndrome was made. The spreading of further cutaneous neoplasms led to a change in immunosuppression: namely, that clinicians suspended tacrolimus and add everolimus. After 2 months, all tumor lesions on the face and on the limbs have disappeared, and no further lesions occurred. Everolimus could represent a valid therapeutical treatment for transplant patients at high risk for cutaneous tumors. A genetic consult and a consequent study of the genetic profile should be performed on each of these patients, to avoid risks of recurrent cutaneous tumors and negative effects on the quality of life.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 04/2015; DOI:10.6002/ect.2014.0208.
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: The outcome of children who had living-donor liver transplant was analyzed according to their status before transplant, and we analyzed the outcome of critically ill patients. MATERIALS AND METHODS: This was a retrospective analysis of children who received primary living-donor liver transplant at Kyoto University Hospital. According to the criteria of the United Network for Organ Sharing, we divided patients into 3 groups: Group A patients had been admitted to the intensive care unit before living-donor liver transplant; Group B patients were hospitalized but did not require intensive care unit stay; and Group C patients were living at home and underwent elective transplant. RESULTS: A total 685 patients met inclusion criteria. Children in Group A were younger than Group B and received liver grafts from younger donors than Group B and C. Group A patients had marked impairment in liver and renal function and coagulation profile and needed higher volumes of fresh frozen plasma transfusions. Group A patients had significantly worse outcomes and early patient death than the other group; Group A patient survival was 68.3%, 63.2%, 60.1%, and 56.1% at 1, 5, 10, and 15 years after living-donor liver transplant (P < .0001). Group A had worse graft survival than other groups (P < .0001), and Group A graft survival was 68.3%, 65.9%, 54.1%, and 49.9% at 1, 5, 10, and 15 years. Low gamma-glutamyl transpeptidase was an independent risk factor for patient death in Group A (hazard ratio, 1.004; 95% confidence interval, 1.0-1.007) (P < .05). Group A patients had a higher rate of multidrug-resistant hospital-acquired infections. CONCLUSIONS: Children who were admitted to the intensive care unit prior to living-donor liver transplant had marked impairment of pretransplant laboratory parameters and worse outcome than other groups.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 04/2015; 13(1):100-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: BK virus infection accompanied with plasma cell-rich infiltrates is a dilemma in renal transplant recipients. One young female patient diagnosed as BK virus-associated nephropathy with plasma cell-rich infiltrates at 16 months after renal transplant was treated with bortezomib and a sequential immunosuppressive protocol of tacrolimus combined with leflunomide. After a short period of reduction, her serum creatinine increased slowly with stable BK viruria. The patient underwent repeat biopsy. The histologic changes showed a decrease in plasma cells and CD20+ cells in the allograft, but the other mononuclear cells showed no difference from the first biopsy. The immunosuppressive protocol was converted to tacrolimus combined with enteric-coated mycophenolate sodium. Her serum creatinine decreased gradually during 6 months of follow-up. We speculate that bortezomib can be used in BK virus-associated nephropathy accompanied with plasma cell-rich infiltrates, and this effect might be mediated through a decrease of plasma cells and CD20+ cells in the allograft. The dosage and time of therapy need to be explored in the future; additional studies of large samples are needed.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 03/2015; DOI:10.6002/ect.2014.0225
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sweet syndrome (acute febrile neutrophilic dermatosis) is a rare clinical entity characterized by skin lesions, neutrophilia, fever, and neutrophilic infiltration of the dermis. It may be a consequence of malignant disease, comorbidities, or drugs. We present a case of acute febrile neutrophilic dermatosis in a patient after autologous stem cell transplant.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 03/2015; DOI:10.6002/ect.2014.0073
  • [Show abstract] [Hide abstract]
    ABSTRACT: Delayed graft function is a significant prognostic indicator after renal transplantation. We hypothesized that delayed graft function is not a single entity, and different patterns of delayed graft function reflect various underlying pathological processes. An analysis of 762 renal transplants was performed, showing serum creatinine was charted serially for the first 30 days after transplant. Measurements were obtained: time on hemodialysis; time to peak creatinine; time for creatinine to half; time for creatinine to within 10% of baseline. Four patterns of delayed graft function were identified. There was no association between pattern of delayed graft function, and 1-year graft survival or serum creatinine at 1 year. Time for creatinine to > 15 days was associated with a higher creatinine level at 1 year than it was with patients with time for creatinine to half < 5 days (300.6 ± 54.3 vs 211.3 ± 26.0 μmol/L; P < .01). Patients with 1-year creatinine concentrations > 180 μmol/L had longer time on hemodialysis and time for creatinine to half than did those with 1-year creatinine concentrations ≤ 180 μmol/L (9.2 ± 1.3 μmol/L vs 7.0 ± 0.7 μmol/L; P = .03; and 11.6 ± 1.7 μmol/L vs 6.0 ± 0.4 μmol/L; P < .001). Time for creatinine to half of 6.5 days (sensitivity 67.3%; specificity 79.4%; area under the curve, 0.70) was the best predictor of a 1-year creatinine concentration ≤ 180 μmol/L. Delayed graft function is not a single entity; rather; it is the most common presentation of a heterogenous variety of pathologies. Its rate of resolution of renal function is the best predictor of long-term graft outcome.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 02/2015; 13(1):19-25. DOI:10.6002/ect.2014.0024
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus recurrence after transplant is universal. Histologic recurrence is observed in > 50% hepatitis C virus-infected grafts within the first year. The primary aim of our study was to evaluate factors responsible for hepatocellular carcinoma recurrence and mortality including histologic markers. All patients who had undergone transplant for hepatocellular carcinoma associated with hepatitis C virus from 2002 to 2012 were evaluated retrospectively. There were 109 patients with hepatocellular carcinoma associated with hepatitis C virus that underwent living-donor liver transplant from July 2002 to June 2012. On univariate analysis, preoperative Model for End-Stage Liver Disease Score (P = .026), α-fetoprotein level (P = .020), rapid fibrosis (P = .008), and Hepatitis Activity Index ≥ 6 (P = .008) were associated with recurrence. On multivariate Cox proportional hazards regression model, Model for End-Stage Liver Disease score (P < .0001) and rapid fibrosis (P = .015) independently predicted hepatocellular carcinoma recurrence. Hepatitis C virus recurrence on biopsy is a poor prognostic indicator and is associated with a higher risk of hepatocellular carcinoma recurrence after liver transplant. Rapid fibrosis after liver transplant independently predicts hepatocellular carcinoma recurrence.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 02/2015; 13(1):46-50. DOI:10.6002/ect.2014.0138
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are increasing numbers of patients on liver transplant waiting lists, and there is a continuing organ shortage crisis. Therefore, more centers and organ procurement organizations are developing protocols for donation after cardiac death. However, the effect of donation after cardiac death allografts on overall patient survival remains controversial, with some centers reporting equivalent patient posttransplant survival but many others indicating increased rates of complications, retransplant, use of resources, and death. Several potential risk factors that predict graft loss and recipient complications have been identified. To improve patient outcomes and reduce dropouts, experimental strategies that target both donors and recipients at various phases of the transplant process have focused on attenuating ischemia-reperfusion injury and have achieved encouraging results. In the present article, our goal is to provide an overview of the current status of, and recent advances in, liver transplant from donation after cardiac death, to better understand the risks and potential benefits of donation after cardiac death liver transplant.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 02/2015; 13(1):6-18. DOI:10.6002/ect.2014.0194
  • [Show abstract] [Hide abstract]
    ABSTRACT: Iloprost has the potential to protect the liver transplant graft before and during cold ischemia. We studied iloprost administration during organ procurement and reperfusion in an extracorporeal pig liver perfusion model. German Landrace pigs (n = 7/group; 22-26 kg each) were used as donors. Preservation was performed by aortic perfusion with 2 L Bretschneiders' Histidine-Tryptophan-Ketoglutarate solution HTK and cold ischemia time (4°C) 20 hours followed by normothermic extracorporeal perfusion for 8 hours. Untreated controls (1) were compared to iloprost (2) donor bolus-treatment (1 μg/kg body weight), (3) addition of iloprost to Bretschneiders' Histidine-Tryptophan-Ketoglutarate solution HTK (0.0125 μg/mL), (4) continuous infusion during reperfusion (2 ng/kg/min), and (5) combined treatment (2) and (4). Iloprost donor treatment led to significantly higher bile production. Addition of iloprost to the preservation solution significantly improved hepatic artery perfusion and was accompanied by improvements of microcirculation and bile production. Iloprost reperfusion treatment alone significantly improved bile production. Enzyme levels were positively affected by all treatment regimens. Combined use of iloprost before and after ischemia improved hepatic artery flow and microcirculation and showed significantly lower hypoxia staining versus controls. Iloprost donor treatment and use of iloprost in the preservation solution significantly improved graft perfusion and function. The effects of graft treatment seemed greater before than after reperfusion. Combined treatment did not reveal a synergistic advantage.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 02/2015; 13(1):51-61. DOI:10.6002/ect.2014.0148
  • Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 02/2015; 13(1):106-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart retransplant is a treatment option for some patients with graft failure. With heart donor short-age, it is important to assess candidates carefully for cardiac retransplant. An adult patient had a successful urgent heart retransplant due to severe toxic cardiomyopathy (anthracycline-induced) after posttransplant lymphoproliferative disease that was a diffuse large B-cell lymphoma.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 01/2015; DOI:10.6002/ect.2014.0077
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study sought to investigate immuno-suppressive medication adherence, therapeutic adherence, school performance, symptom experiences, and depression levels of patients having undergone liver transplant during childhood. We performed a retro-spective, cross-sectional, case-controlled study to compare the depression levels of subjects with those of their healthy peers. Data were collected between June 23, 2014, and July 10, 2014 from 0- to 18-year-old patients having undergone a liver transplant between 1996 and 2014 (n = 27; the participant's mean age, 17.59 y [SD = 4.29, min-max = 8-28 y]). The mean score for the immunosuppressant therapy adherence was 11.18. To collect the data, the Demographic and Clinical Characteristics Form, Immunosuppressant Therapy Adherence Scale, Therapeutic Regimen Adherence Assessment Questionnaire, School Performance Assessment Questionnaire, Modified Transplant Symptom Occurrence and Symptom Distress Scale-58, and Beck Depression Inventory were used. To analyze the data, descriptive statistics (frequencies, mean, and standard deviation), Mann-Whitney U test, and ridit scoring were used. While the rate of adherence with clinical appointments was 55.5%, it was 33.3% with the diet (prescribed regime) and 44.4% with exercise. While 33.3% of the participants repeated a grade or were held back, 44.4% of them missed more than 20 school days. Of the symptoms, the recipients mostly experienced anxiety, restlessness, nervousness, fatigue, and difficulty in concentrating. The patients> mean depression score was 7.77 when they were compared to their healthy peers, the difference was not statistically significant (P > .05). In our study, the recipients> adherence with immunosuppressive therapy and clinical appointment was high. This study will provide data for the literature about pediatric liver transplant recipients> adherence with diet and exercise, and physiological and psychological symptoms such as fatigue and anxiety.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 01/2015; DOI:10.6002/ect.2014.0150
  • Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 01/2015;
  • Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 01/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Developments in transplantation have progressed dramatically over the past century. Current research is underway to optimize immune modulation, genetically engineering animals for xenografting, and breakthroughs are occurring in regenerative medicine. However, pioneering live-donor transplantation has transformed transplantation in the organ shortage, and these contribute an increased proportion of transplanted organs. Live-donor transplantation is associated with better long-term outcomes, and techniques to recover organs have become less invasive. We set out to examine the evolution of transplantation from its historical beginnings to the developments that make it successful today.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 12/2014; 13(1). DOI:10.6002/ect.2014.0258
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infection after solid-organ transplantation is known as a severe complication and carries with it a high risk of infection-related mortality. Among patients after heart transplant Aspergillus species most often cause atypical pneumonia. The incidence of invasive aspergillosis after heart transplant has been reported from 3% to 14%. It is the opportunistic pathogen with the highest mortality, ranging from 50% to 80%. Prompt antifungal therapy is crucial, but rapid diagnostic procedures with sufficient sensitivity and specificity are lacking at the moment. We present a rare case of a patient with massive metastasizing invasive aspergillosis within 1 month after heart transplant, undetected before death.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 12/2014; DOI:10.6002/ect.2014.0115
  • [Show abstract] [Hide abstract]
    ABSTRACT: To develop a new parathyroid allotransplant method for the treatment of permanent hypoparathyroidism. Parathyroid cells 50 × 106 derived from a parathyroid hyperplasia patient were transferred to a 61-year-old patient who had thyroidectomy 17 years earlier, allowing to papillary thyroid cancer; he was admitted to our outpatient clinic with symptomatic chronic hypocalcemia. Cell isolation, cryopreservation, and culturing were conducted according to a new protocol. During a follow-up of 5 months, the patient had no complications that could indicate rejection, and clinical symptoms completely resolved without requiring any drug supplementation. Here, we report a new method, enabling fast and cost-effective parathyroid allotransplant with maintained tissue viability sufficient to treat persistent hypocalcemia.
    Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 12/2014; DOI:10.6002/ect.2014.0110